← Back to Clinical Trials
Recruiting NCT06927804

NCT06927804 Utilization of Virtual Reality to Increase Comfort and Reduce Procedural Distress During Port Insertion Into the Body

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06927804
Status Recruiting
Phase
Sponsor University Hospital Ostrava
Condition Oncology Patients
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-07-01
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Virtual reality interventionStandard Care (in control arm)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-07-01 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomised controlled study evaluates whether virtual reality (VR) can support patient comfort and help reduce anxiety and stress during subcutaneous venous port implantation in adult oncology patients. Patients will be assigned to standard care or standard care with VR intervention. Subjective and objective measures of stress and discomfort will be collected, including the Visual Analog Scale (VAS) for self-reported procedural discomfort, physiological parameters (blood pressure, heart rate, variability), the STAI-6 questionnaire, and salivary cortisol. The study aims to explore the potential of VR as a non-pharmacological, immersive tool to improve procedural experience and reduce psychological distress in patients undergo-ing minor oncological procedures.

Eligibility Criteria

Inclusion Criteria: * Patients \> 18 years of age * Signed Informed Consent Form * Patients Indicated for oncology treatment administration using subcutaneous port Exclusion Criteria: * Not signing of the Informed Consent Form * Patients \< 18 years of age * Patients unsuitable for subcutaneous port implantation

Contact & Investigator

Central Contact

Jiří Hynčica

✉ jiri.hyncica@fno.cz

📞 0042059737

Principal Investigator

Lukáš Knybel, Ing., PhD

PRINCIPAL INVESTIGATOR

University Hospital Ostrava

Frequently Asked Questions

Who can join the NCT06927804 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Oncology Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06927804 currently recruiting?

Yes, NCT06927804 is actively recruiting participants. Contact the research team at jiri.hyncica@fno.cz for enrollment information.

Where is the NCT06927804 trial being conducted?

This trial is being conducted at Ostrava, Czechia.

Who is sponsoring the NCT06927804 clinical trial?

NCT06927804 is sponsored by University Hospital Ostrava. The principal investigator is Lukáš Knybel, Ing., PhD at University Hospital Ostrava. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology